Lancashire and South Cumbria
Formulary
Formulary
6 Endocrine system
06-07-02 Gonadorelin analogues
Trusts may in some cases, retain responsibility for the supply of GnRH analogues where this is judged to be appropriate.
GnRH analogues for endometriosis/uterine fibroids beyond 6 months treatment (off-license use) should not be supplied in primary care.
| Leuprorelin Prostap® SR, Prostap® 3 |
|
Formulary
|
Injection 3.75mg, 11.25mg vial with vehicle filled syringe |
|
| Triptorelin Decapeptyl® SR |
|
Formulary
|
Injection, (powder for suspension), m/r, triptorelin (as acetate),3-mg vial (with diluent, 11.25-mg vial (with diluent), 22.5mg vial (with diluent) |
 LSCMMG: Triptorelin NMR |
|
|
Links
- LSCMMG: Trans Female Gender Dysphoria Information Sheet
- LSCMMG: Trans Male Gender Dysphoria Information Sheet
- LSCMMG: Triptorelin NMR
- NICE HST21: Setmelanotide for treating obesity caused by LEPR or POMC deficiency
- NICE HST31: Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome
- NICE TA832: Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids
- NICE TA996: Linzagolix for treating moderate to severe symptoms of uterine fibroids